AMLX · Amylyx Pharmaceuticals Inc
AI read · Neutral
The AI's read
Amylyx set a Phase 3 LUCIDITY top-line readout for this week for avexitide, a first-in-class GLP-1 antagonist targeting post-bariatric hypoglycemia. That’s a binary event that can move the stock a lot on the headline. The market already bid AMLX up roughly 11% in after-hours and the stock is trading near its 52-week highs, so some upside is already priced in. RSI is about 60, so momentum exists but it isn’t overheated. Catalyst is fresh and market-moving, but approval probability is unknown and outcomes are binary. We lean neutral until the readout lands and then reassess based on the actual data and guidance.